VistaGen Therapeutics (NASDAQ:VTGN) Upgraded to "Hold" at Wall Street Zen

Key Points

• VistaGen Therapeutics has been upgraded from a "sell" rating to a "hold" rating by Wall Street Zen, indicating a shift in analysts' perception of the company's stock.
• The stock experienced a 12.2% gain, opening at $3.31, with a market capitalization of approximately $101.55 million.
• Institutional investors own 78.39% of VistaGen's stock, with notable recent increases in holdings from firms such as Jane Street Group and ADAR1 Capital Management.

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Saturday.

Separately, William Blair reiterated an "outperform" rating on shares of VistaGen Therapeutics in a research report on Wednesday, June 18th. One research analyst has rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of "Buy".

VistaGen Therapeutics Stock Down 2.2%

Shares of VTGN traded down $0.07 during trading hours on Friday, reaching $3.10. 519,565 shares of the company traded hands, compared to its average volume of 711,942. The stock has a market capitalization of $95.11 million, a PE ratio of -1.74 and a beta of 0.40. VistaGen Therapeutics has a fifty-two week low of $1.90 and a fifty-two week high of $3.79. The stock has a fifty day simple moving average of $2.55 and a 200 day simple moving average of $2.51.

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.47) EPS for the quarter, meeting analysts' consensus estimates of ($0.47). The business had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.22 million. VistaGen Therapeutics had a negative return on equity of 74.06% and a negative net margin of 6,777.08%. Research analysts predict that VistaGen Therapeutics will post -1.77 EPS for the current fiscal year.

Institutional Investors Weigh In On VistaGen Therapeutics

Several hedge funds have recently modified their holdings of the stock. Stempoint Capital LP raised its holdings in shares of VistaGen Therapeutics by 2.0% during the 2nd quarter. Stempoint Capital LP now owns 2,413,254 shares of the company's stock valued at $4,827,000 after buying an additional 46,700 shares during the period. Nantahala Capital Management LLC raised its holdings in shares of VistaGen Therapeutics by 30.6% during the 4th quarter. Nantahala Capital Management LLC now owns 1,981,980 shares of the company's stock valued at $5,847,000 after buying an additional 464,284 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of VistaGen Therapeutics by 4,826,425.0% during the 4th quarter. JPMorgan Chase & Co. now owns 772,244 shares of the company's stock valued at $2,278,000 after buying an additional 772,228 shares during the period. ADAR1 Capital Management LLC raised its holdings in shares of VistaGen Therapeutics by 246.4% during the 1st quarter. ADAR1 Capital Management LLC now owns 420,765 shares of the company's stock valued at $1,052,000 after buying an additional 299,304 shares during the period. Finally, Almitas Capital LLC purchased a new stake in shares of VistaGen Therapeutics during the 4th quarter valued at about $751,000. 78.39% of the stock is currently owned by hedge funds and other institutional investors.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.